West Chester, PA, United States of America

Gary G Liversidge

USPTO Granted Patents = 29 (Patent Applications = 17)

CIPO Patents = 1

EPO Patents = 4 (Patent Applications = 3)

Average Co-Inventor Count = 3.6

ph-index = 21

Forward Citations = 2,988(Granted Patents)

Company Filing History:

10 out of 80

Elan Pharma International Limited

Alkermes Pharma Ireland Limited

patents

4. 4 out of 21,594

Eastman-kodak Company

patents

5. 2 out of 206

Sterling Winthrop Inc.

Years Active: 1992-2014

Loading Chart...

29 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 8623412 - Abuse-resistant pharmaceutical compositions (2014-01-07),

2. 8367112 - Nanoparticulate carverdilol formulations (2013-02-05),

3. 8309133 - Nanoparticulate quinazoline derivative formulations (2012-11-13),

4. 8293277 - Controlled-release nanoparticulate compositions (2012-10-23),

5. 8236352 - Glipizide compositions (2012-08-07),

6. 8158153 - Nanoparticulate bisphosphonate compositions (2012-04-17),

7. 8119163 - Nanoparticulate and controlled release compositions comprising cefditoren (2012-02-21),

8. 8003127 - Nanoparticulate corticosteroid and antihistamine formulations methods of making, and methods of administering thereof (2011-08-23),

9. 7910577 - Injectable nanoparticulate olanzapine formulations (2011-03-22),

10. 7825087 - Nanoparticulate and controlled release compositions comprising cyclosporine (2010-11-02),

11. RE41884 - Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions (2010-10-25),

12. 7763278 - Nanoparticulate polycosanol formulations and novel polycosanol combinations (2010-07-27),

13. 6432381 - Methods for targeting drug delivery to the upper and/or lower gastrointestinal tract (2002-08-13),

14. 6221400 - Methods of treating mammals using nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors (2001-04-24),

15. 6068858 - Methods of making nanocrystalline formulations of human immunodeficiency (2000-05-30),

Title: **Gary G. Liversidge: Innovator in Pharmaceutical Compositions**

Introduction

Gary G. Liversidge is a prolific inventor based in West Chester, Pennsylvania, with a remarkable portfolio of 29 patents to his name. His contributions primarily focus on pharmaceutical innovations designed to enhance drug efficacy while minimizing potential abuse, thereby addressing critical needs in modern medicine.

Latest Patents

Among his latest patents is an invention for **abuse-resistant pharmaceutical compositions**, which details a controlled release composition that employs discrete particles of an active pharmaceutical ingredient. This formulation is designed with a water-insoluble coating material, making it difficult to separate from the matrix, thereby reducing the potential for misuse. Additionally, his patent for **nanoparticulate carvedilol formulations** highlights his commitment to advancing pharmacological efficacy. This invention boasts improved pharmacokinetic profiles and bioavailability, featuring an effective average particle size of less than about 2000 nm.

Career Highlights

Gary G. Liversidge has made significant strides in his professional journey, collaborating with leading companies in the pharmaceutical sector. He has held positions at Elan Pharma International Limited and Nanosystems L.L.C., where he has been instrumental in the development and refinement of novel drug formulations.

Collaborations

Throughout his career, Gary has worked closely with notable colleagues such as Stephen B. Ruddy and Scott Jenkins. These collaborations have further propelled his innovations in the field, leading to groundbreaking advancements in pharmaceutical compositions and therapeutic delivery systems.

Conclusion

Gary G. Liversidge is undoubtedly a noteworthy figure in the realm of pharmaceutical innovations. His extensive work in developing abuse-resistant medications and improving drug formulations emphasizes the critical intersection of technology and healthcare. With numerous patents and impactful collaborations, he continues to contribute to the future of pharmaceuticals.

This text is generated by artificial intelligence and may not be accurate.